“
TL;DR
This study used mass spectrometry to profile the blood serum proteome of COVID-19 patients and integrated it with in vitro infection experiments.
Nature Communications · 14 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study used mass spectrometry to profile the blood serum proteome of COVID-19 patients and integrated it with in vitro infection experiments.
The HiRIEF LC-MS/MS platform quantified approximately 2000 proteins, revealing elevated levels of interferon- and proteasome-related proteins in patient serum, which correlated with disease severity. In vitro experiments showed proteome changes at days 3 and 7 post-infection, including increases in immunoproteasome subunits. Limitations include the use of a cancer-derived cell line for in vitro work and the challenge of distinguishing organ-specific from systemic proteome changes. The findings suggest that blood protein alterations reflect a combination of direct cellular infection responses and systemic inflammation, offering potential biomarkers for COVID-19.